budigalimab + pemetrexed + cisplatin

**Budigalimab + pemetrexed + cisplatin** is an investigational combination regimen being studied primarily for **untreated metastatic non-squamous non-small cell lung cancer (NSCLC)**. Budigalimab is a human monoclonal antibody targeting the programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor. Pemetrexed is a multi-targeted antifolate antineoplastic agent, and cisplatin is a platinum-based chemotherapy drug that induces DNA crosslinking and damage. The combination seeks to leverage the immunomodulatory effects of PD-1 blockade along with dual cytotoxic antineoplastic mechanisms to enhance anti-tumor efficacy in first-line NSCLC therapy[2][3][5]. Budigalimab is under development by AbbVie; pemetrexed and cisplatin are established chemotherapeutic agents.